CTOs on the Move

CytoVale

www.cytovale.com

 
Cytovale, based in San Francisco, Calif., is a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, and applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cytovale.com
  • 150 Executive Park Blvd Suite 4100
    San Francisco, CA USA 94134
  • Phone: N/A

Executives

Name Title Contact Details

Funding

CytoVale raised $15M on 10/30/2019

Similar Companies

Bioreclamation

Bioreclamation is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DTx Pharma

DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.

Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

moksha8 Pharmaceuticals

moksha8 Pharmaceuticals is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avanir

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.